About DupCheck

DupCheck is a web-based tool used globally to screen for duplicate patients in clinical trials across studies, sponsors and therapeutic areas. Duplicate enrollment harms both patients and studies.In many therapeutic areas even a small number of duplicate patients can lead to a negative or failed trial.  In addition enrolling duplicate patients can result in a misattributed serious adverse event.

DupCheck is part of NEWMEDS an international consortium of scientists that has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs.  NEWMEDS brings together top scientists from academic institutions with a wide range of expertise, and partners them with nearly all major biopharmaceutical companies.  NEWMEDS ultimate goal is to develop new approaches for shorter and more efficient trials of new medications. 

DupCheck provides sites and sponsors with real time information on attempted duplicate enrollment at time of screening. DupCheck can also screen for previous participation in a trial of investigational drug. 

DupCheck can be linked to existing electronic data capture systems—eliminating additional data entry—and run in the background, analogues to an anti-virus.  

DupCheck is compliant with EU General Data Protection Regulation (GDPR) and HIPAA.  No identifiable patient or sponsor data is transmitted, stored or shared.  

DupCheck was given a favorable Qualification Advice review by the European Medicines Agency and the FDA has stated that DupChecking is advisable.


DupCheck is available for integration with: 

DupCheck is an ACRES ally

For more information, sponsors, investigators and regulators please contact us at: Contact@DupCheck.org

Core Team

Jonathan rabinowitz

Founding Director

Jonathan Rabinowitz, PhD is the founding director of DupCheck.  He is the Elie Wiesel Professor at Bar Ilan University and a visiting professor at Mount Sinai School of Medicine in New York.  His research focuses on improving efficiency of clinical trials.  He has over 25 years of experience in managing and analyzing large data sets and in developing and implementing statistical algorithms in pharmaceutical, services and epidemiological datasets.  He is the academic lead of the Advanced Data Analysis Techniques group at IMI/EFPIA sponsored NEMWEDS, one of the largest ever research academic-industry collaboration projects directed at finding new methods for drug development.  He did doctoral training in Statistics at Bar Ilan University and in Social Welfare at Yeshiva University.  He serves on advisory groups at FDA and EMA.  He is a member of the American College of Neuropsychopharmacology.  He is on the Executive Committee of International Society for CNS Clinical Trials and Methodology and also serves as co-chair of the working group on consistency in measurement.  He has served as a member of the DIA Scientific Working Group on Missing Data in Clinical Trials.  He has over 170 scientific publications. 

Chief Technology Officer

Mr. Alexey Abraham has over 20 years of software development experience. Among them 8 years in product and project management of complex software projects in different countries.
The companies, he has worked for include: Intel, Orange UK, Comverse, NOVA, Matrix, Zoral Labs, Gat Systems, FinalView, Towndwarf Co., Control&Robotics Solutions. Alexey has vast experience in server side and front end development, computer security, complex web systems, mobile development for different platforms, low level programming for Windows & Linux, surveilance and image recognition systems, banking.

Lead Developer 

Yosef Stefansky, has extensive software development and project management experience.  He held developer and team positions in the Israel Defense Forces (IDF) and Israel Aerospace  Industries (IAI).  Mr. Stefansky has deep pockets of expertise in high security database architecture and system security.  

Legal Services

Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.


efpia newmeds imi eu acres